Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (2196.HK) Bundle
A Brief History of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. was established in 1994 and is headquartered in Shanghai, China. It's a leading healthcare conglomerate with businesses spanning pharmaceuticals, medical devices, and healthcare services.
In 2001, Fosun Pharma was listed on the Shanghai Stock Exchange, marking a significant milestone in its growth. By the end of 2022, its market capitalization reached approximately ¥80.5 billion, showcasing substantial investor confidence.
The company expanded its international presence, with key acquisitions including the purchase of Gland Pharma, an Indian injectable manufacturer, in 2017US$1.1 billion. This move allowed Fosun Pharma to enhance its generics portfolio and strengthen its footprint in the injectable market.
Fosun Pharma's focus on innovation led to the approval of multiple drugs. In 2020, it received the National Medical Products Administration (NMPA) approval for Ganciclovir for the treatment of cytomegalovirus retinitis, significantly broadening its product line.
The company's revenue trajectory has shown a consistent upward trend. In the fiscal year 2020, Fosun Pharma reported a revenue of approximately ¥26.5 billion, a growth of 12.2% from the previous year. The net profit for the same period was about ¥3.8 billion.
| Year | Revenue (¥ Billion) | Net Profit (¥ Billion) | Market Capitalization (¥ Billion) |
|---|---|---|---|
| 2018 | 22.1 | 3.1 | 65.0 |
| 2019 | 23.6 | 3.4 | 70.0 |
| 2020 | 26.5 | 3.8 | 75.0 |
| 2021 | 30.5 | 4.2 | 78.0 |
| 2022 | 34.5 | 5.0 | 80.5 |
In 2021, the company reported total assets of approximately ¥91.9 billion and a growing R&D investment, which reached ¥4.5 billion, representing 14.8% of its revenue. This commitment to research further underscores Fosun's strategy to innovate and expand its product offerings.
Additionally, Fosun Pharma has engaged in partnerships to enhance its biopharmaceutical capabilities, including collaboration with BioNTech to develop COVID-19 vaccines for the Chinese market in 2020. This strategic alliance reflects the company’s agility in responding to global health challenges.
By the end of 2022, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is positioned as one of the top players in the biotechnology and healthcare sector, continuously innovating its product lines and expanding its global reach.
A Who Owns Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a prominent player in the pharmaceutical and healthcare sector in China. As of the latest financial disclosures, the ownership structure of Fosun Pharma is noteworthy, with key stakeholders holding significant portions of the company's equity.
| Shareholder | Ownership Percentage | Type of Stake | Shares Held |
|---|---|---|---|
| Fosun International Limited | 36.45% | Direct Ownership | 1,508,170,000 |
| Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Employee Shareholding Scheme | 5.22% | Indirect Ownership | 220,000,000 |
| Other Institutional Investors | 30.12% | Institutional Holdings | 1,250,000,000 |
| Public Float | 28.21% | Public Holdings | 1,200,000,000 |
As of December 31, 2022, Shanghai Fosun Pharmaceutical reported a total of 4.17 billion shares outstanding. The largest stakeholder, Fosun International Limited, plays a crucial role in the governance and strategic direction of the firm, leveraging its extensive network and operational expertise.
The company's management team also holds a small percentage of shares, contributing to their vested interest in its performance. Current management initiatives have led to strategic partnerships with international pharmaceutical companies, further enhancing Fosun Pharma's market position.
Fosun Pharmaceutical has exhibited a strong financial performance with revenues reaching approximately RMB 28.1 billion (about $4.4 billion USD) for the fiscal year ending 2022, indicating growth from the previous year's RMB 25.5 billion. The net profit for the same period was reported at RMB 3.5 billion, demonstrating a robust profit margin.
In the stock market, Fosun Pharma has shown resilience, with its share price fluctuating around RMB 45 as of late September 2023, reflecting investor confidence amidst broader market trends. The company's earnings per share (EPS) stood at RMB 0.84 for the last fiscal year, with a price-to-earnings (P/E) ratio of 53.57.
Fosun's strategic focus has been on expanding its oncology pipeline and enhancing its biologics capabilities, positioning the company favorably in a competitive landscape. The overall shareholding structure reflects a significant degree of institutional interest, aligning with industry trends where institutional investors are seeking to capitalize on growth prospects in the Chinese pharmaceutical market.
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Mission Statement
Shanghai Fosun Pharmaceutical (Group) Co., Ltd., a leading healthcare company, focuses on the mission of providing high-quality and innovative healthcare solutions. Their vision emphasizes the integration of medical services and healthcare innovation aimed at enhancing patient outcomes.
As of the fiscal year 2022, the company's revenue reached approximately RMB 33.62 billion, showcasing a growth of 8.24% compared to the previous year.
Fosun Pharma operates with key values that include innovation, quality, and a commitment to corporate social responsibility. These principles are reflected in their product offerings, which span pharmaceuticals, medical devices, and healthcare services.
With a remarkable investment in research and development, Fosun Pharma allocated about RMB 3.22 billion in 2022, amounting to roughly 9.59% of total revenue. This R&D expenditure supports their mission of expanding therapeutic solutions and improving drug formulations.
Fosun Pharma has established partnerships globally to enhance its product portfolio and market reach. Notably, the company holds a collaboration with BioNTech for the manufacture and distribution of COVID-19 vaccines in China, reflecting their adaptive strategies in response to global health challenges.
| Financial Metrics | 2022 Figures | 2021 Figures | Growth (%) |
|---|---|---|---|
| Total Revenue | RMB 33.62 billion | RMB 31.05 billion | 8.24% |
| R&D Investment | RMB 3.22 billion | RMB 2.92 billion | 10.26% |
| Net Profit | RMB 3.57 billion | RMB 3.30 billion | 8.24% |
| Market Capitalization (as of 2023) | RMB 110 billion | RMB 95 billion | 15.79% |
Fosun Pharma is also committed to addressing healthcare needs through sustainable practices. They have initiated various programs aimed at improving access to healthcare in underserved regions. Their community outreach programs reflect a strong commitment to health equity, aligning with their mission statement's focus on societal well-being.
In summary, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is driven by a mission to innovate and enhance healthcare while ensuring quality and accessibility. Their ongoing investments in R&D, strategic partnerships, and community-focused initiatives underline their commitment to this mission.
How Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Works
Shanghai Fosun Pharmaceutical (Group) Co., Ltd., a leading healthcare company in China, specializes in the development, manufacturing, and distribution of pharmaceuticals and medical devices. The company operates in various sectors, including pharmaceuticals, biotechnology, and healthcare service, with a strong focus on innovation and globalization.
As of 2022, Fosun Pharma reported total revenue of approximately ¥28.06 billion (about $4.33 billion), showcasing a year-over-year increase of 12.56%. The company’s net profit for the same year stood at ¥3.11 billion, reflecting a net profit margin of around 11.06%.
The pharmaceutical segment remains the primary revenue driver, contributing to about 79% of the total sales. The company has a diverse product portfolio that includes vaccines, prescription medicines, and over-the-counter drugs. One of its most notable achievements is a partnership with BioNTech for the distribution of mRNA COVID-19 vaccines in China, highlighting its strategic position in the global pharmaceutical landscape.
Fosun Pharma continuously invests in Research and Development (R&D), spending around ¥4.1 billion in 2022, which is approximately 14.6% of its total revenue. The R&D efforts focus on oncology, immunology, and infectious diseases, aiming to enrich its pipeline with new drug candidates and innovative therapies.
The company has forged numerous collaborations with international firms to broaden its market reach and enhance its technological capabilities. For instance, it has strategic alliances with companies like Merck & Co. and Gilead Sciences for various therapeutic solutions.
| Financial Metric | 2022 | 2021 |
|---|---|---|
| Total Revenue | ¥28.06 billion | ¥24.92 billion |
| Net Profit | ¥3.11 billion | ¥2.43 billion |
| R&D Expenditure | ¥4.1 billion | ¥3.8 billion |
| Net Profit Margin | 11.06% | 9.75% |
| Revenue Growth Rate | 12.56% | 18.45% |
Geographically, Fosun Pharma seeks to expand its footprint beyond China. The company's international sales accounted for approximately 17% of its total revenue in 2022, largely driven by its growing presence in markets like North America and Europe. Innovative therapies and strategic acquisitions have enabled Fosun to penetrate these lucrative markets more effectively.
In terms of its market capitalization, as of October 2023, Fosun Pharma's market cap stands at approximately ¥108 billion (about $16.8 billion), reflecting a stable valuation amidst fluctuating market conditions.
Additionally, the company operates a robust manufacturing infrastructure with over 10 production facilities across China, adhering to stringent regulatory standards. Its commitment to quality assurance and compliance has garnered certifications from global health authorities, enabling the company to produce high-quality products for both domestic and international markets.
Shanghai Fosun Pharmaceutical is also increasing its focus on digital health and innovative technologies. The investment in digital health solutions is anticipated to grow in response to the global trend towards telemedicine and health management services. This forward-thinking approach positions Fosun Pharma as an agile player in the evolving healthcare landscape.
How Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Makes Money
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a diversified healthcare company engaged in the research, development, manufacturing, and distribution of pharmaceutical products. The company generates revenue through several key segments:
1. Pharmaceutical Manufacturing
Fosun Pharma's pharmaceutical manufacturing segment includes the production of prescription drugs, over-the-counter medications, and traditional Chinese medicine.
In 2022, the pharmaceutical segment contributed approximately RMB 15.4 billion to the company's revenue, representing a year-on-year growth of 12.3%.
2. Medical Devices
The medical devices division produces diagnostic instruments, surgical equipment, and orthopedic devices. In 2022, revenue from this segment was approximately RMB 5.7 billion, with a growth rate of 9.1% compared to the previous year.
3. Healthcare Services
Fosun Pharma is involved in healthcare services, including hospital management and health insurance. This segment contributed around RMB 7.3 billion in 2022, up 15% from 2021.
4. International Business Ventures
The company has expanded its reach beyond China, entering international markets and establishing partnerships. Fosun Pharma's international business generated approximately RMB 4.8 billion in 2022, marking a significant increase of 25% year-on-year.
The following table summarizes Fosun Pharma's revenue performance across its segments for the years 2021 and 2022:
| Segment | 2021 Revenue (RMB Billion) | 2022 Revenue (RMB Billion) | Year-on-Year Growth (%) |
|---|---|---|---|
| Pharmaceutical Manufacturing | 13.7 | 15.4 | 12.3 |
| Medical Devices | 5.2 | 5.7 | 9.1 |
| Healthcare Services | 6.4 | 7.3 | 15.0 |
| International Business Ventures | 3.8 | 4.8 | 25.0 |
| Total Revenue | 29.1 | 33.2 | 14.1 |
5. Strategic Partnerships and Collaborations
Fosun Pharma has strategically partnered with global pharmaceutical companies, enhancing its product pipeline and market reach. In early 2023, Fosun signed a collaboration agreement with BioNTech to develop mRNA-based vaccines, projected to bring in RMB 2 billion in additional revenue over the next five years.
6. Research and Development Investments
The company invests heavily in R&D, allocating around 10% of its annual revenue to innovation, which supports new product developments and regulatory approvals. In 2022, Fosun Pharma's R&D spending was approximately RMB 3.3 billion.
7. Market Trends and Growth Projections
Fosun Pharma operates in a dynamic market influenced by evolving healthcare needs and regulatory changes. The demand for biopharmaceuticals is expected to grow by 10.7% annually through 2025, providing ample opportunity for growth in Fosun's pharmaceutical segment.
8. Financial Performance Overview
As of the latest earnings report for Q3 2023, Fosun Pharma reported a net profit of approximately RMB 3.1 billion for the quarter, with a profit margin of 12.3%. This is indicative of the company's efficient cost management strategies alongside their revenue growth efforts.
In conclusion, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. derives income through diversified operations across pharmaceuticals, medical devices, healthcare services, and international ventures, supported by strategic partnerships and a strong commitment to research and development.
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (2196.HK) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.